Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
From tonights 10Q - Management’s Plan - In the past, the Company has incurred substantial losses and negative cash flows from operating activities. For the year ended December 31, 2007, the Company incurred a loss from operations of $661,737 and has a working capital deficiency and a shareholders’ deficit as of December 31, 2007. However, the Company generated positive cash flows from operations of $594,912 and $478,500 for the years ended December 31, 2007 and 2006, respectively. Furthermore, since December 31, 2007 the Company has received cash from the sale of patents and unregistered securities and through additional short term borrowings from BFI. As a result, management believes the Company has sufficient cash to fund operations in the near term.
I personally think that APNO management are a bunch of idiots. I've sold some of my shares, but I'll hold on to the rest for a little while longer.
as you can tell from my post, I'm not a happy camper re APNO/management - but hanging in to see what develops as valuation leaves plenty of room for improvement...
Think we posted about the same time. This one is wearing on my patience. I have held it since the merger when the cash value was much more than the pps. Now that advantage is gone, but it appears there is a real company here. So I hold hoping that someone else decides this company has value. Hopefully, this will be the year they start making $ and increase revenues. Jim
Someone just sold at .65. Guess they did not understand the filing. Even though 250k shares were added, they were at .85 and bring cash into the company. Not really a problem. Jim
good thing management keeps the lid on company information or the price could be higher...
Filing just out. Snieder added 250k shares at .85. Directly from the company. So we have some dilution. Jim
Was expecting .50 today and now the I see a bid ut from .65 to .75. Go figure. Jim
Decided to jump in here .80 - not quite down to my target, but I figure APNO could change on a dime so to speak.
I've been trying to add .65-.75 area. Figured with tax loss selling that might be possible. However, real hard to predict given the lack of real chart and statistical significance to any trading.
"Wait 'till next year??"
Not yet, but may. With tax selling this one may go down a lot more. For some reason it has been at .65 in my portfolio balances with schwab. When it does not trade, they usually place its value at the last regular session bid, but lately they have picked a bid much lower. Sure makes my portfolio look sad. Anyway, without news, I see no reason to not add below a buck. Jim
Has anybody been buying recently at these lower prices? I'm kind of worried.
Tax selling season is here. Look for APNO to take quite a hit. Bid lowest in months now at .90. Jim
Some stock trading last couple of days - APNO released earnings last year on 11/01 so 3Q results should be out soon...
Alpha announces new partnership with R & C Biogenius LTD. Here is a link to their website - http://www.rcbiogenius.com.hk/
Not too impressive. Hope there is more to this than meets the eye.
This link is to some of the work their scientists have been involved with - http://www.devicelink.com/ivdt/archive/06/03/013.html Jim
I don't know about you guys' experience with ARCA, but they always come with size and it's a very good sign for the stock whenever you see them on the bid. ARCA is always patient and would rather take in a lot of shares at the bid, before they go chasing the ask though.
Thanks for posting that re APNO. Aside from his apparent indifference to investor relations, the info seems pretty promising, share structure to remain tight and revenues to increase domestically, and expenses to stay stable or even reduce as a percentage of sales.
Can't ask for much more than that in perhaps too quiet a way. LOL
if he reads this board you did! but given your discussion I doubt he'd bother - I do own a number of small public companies that have a low to no level of investor communication and they blame reg FD or cost savings but it seems the ability to operate with as little public scrutiny/interference as possible is the biggest factor - there may be a good result on a long-term basis but it makes monitoring the company very difficult for public investors...
I didn't actually call him an idiot...just thought it very loudly! :)
Thanks very much for your phone call post - APNO obviously did the XTRN deal to access the cash in a less dilute transaction than raising more VC capital NOT for the public cap, but to do the deal and then clamp down on communication with public shareholders is bull$hit - look for insider buying at attractive prices once a catalyst is in sight! - Snider has also clammed-up in the past year so its not just Bissinger - referring to him as an "idiot" may also hurt your chances of a return call!! - anyway, there is a level of shareholder communication small companies can do without it becoming promotional or damaging, competition-wise - hopefully APNO figures out how to approach it more effectively - thanks again...
Overall, I though the call was a 4 (out of 10). I still like the company and their growth prospects, but I think that Ron is an idiot.
I encourage everyone to please call the company and see if they will return your call. Demand that you speak with Ron and let's change his mind that he doesn't need to return investor phone calls. Even if you only have a 2-3 questions, it would be worth it just to see if they will take/return your call.
He told me (after I told him that he was ridiculous in his thinking) that he would return my calls from now on, but I still don't get the impression that he would return everyone's calls.
Call with Ron...
First of all, I must say that I was not at all impressed with Ron. I spoke with Darryl Ray while he was still with the company and he was pretty helpful and actually returned my call. The first thing that Ron told me was that he believes everything that I need to know is the filings and as a public company, he didn't feel it was necessary to take investor calls because of that reason. (Huge No-No in my book!) After almost having a cow at this comment, I decided to continue the call anyway, despite my gut feeling of just hanging up the phone and immediately selling my shares (which I really couldn't do because it was 5:30 on Friday).
1) GE relationship - The GE business remains a very signficant portion of their business and things are going very well.
2) Sales growth in US slower than International sales - International sales (especially Asia) has been very strong as this is a growing market for microarray technologies. Asia will remain a very strong market for the forseeable future. In the US, sales have slowed as they transition from a distributor infrastructure to a direct sales method. Once this transition is completed, sales should accellerate. Using direct sales will have a little higher costs, but the increased revenues will more than make up for it (by a long shot).
3) Does APNO have recurring revenues? - Not a lot of recurring revenues; some consumables, but not a major part of their business.
4) Why do people buy from APNO when they could buy from Perkin-Elmer ($3 billion market cap) or Molecular Devices (~$1 billion)? - APNO has better capabilities in their microarrays and better support, along with an overall better product. A good example of better support from APNO is that PKI and MDC won't demo a product before they sell it. APNO does and the customers like that.
5) Does hiring Mark Allen open up windows to sales in Asia? - Mark has a lot of experience in Asia from Molecular Devices and should help us accellerate sales to Asia and increase our opportunities there.
6) R&D expenditures have declined as a % of sales versus last year...are you sacrificing future growth for short-term profitability? - The long period of investment in their newest microarray reached the end of its development cycle. APNO is currently running at a normal R&D run rate. The company is also lowering its R&D expense by partnering with other companies to do development of new products and allows them to take advantage of a greater talent and resource pool.
7) Any plans to bring on a new CFO? - No near term plans to bring on a CFO, APNO would rather put money back into the direct sales team and R&D.
8) What is going to happen with the $1.5 million in short-term debt that is due? - First of all, the the ST debt rolls over each year. APNO is very reluctant to do a stock offering (no dillution) and is currently looking to put the cash that it makes back into the business.
9) Why no public PRs about the AlphaImager and AlphaView? - The Business Wire service didn't post it (it was there fault) because they "sometimes leave out smaller company's PRs because they won't have as big of an impact on the market as putting out a PR on a $10 billion company." (Beigledog's note: That's insane!) However, these products are just product extensions of current products and aren't really game changers for APNO.
10) How much of the business is seasonal and why? - It always seems like 4th quarter is the best quarter, but there is no reason for it to be this way.
11) When will the expenses due to Haseeb and Darryl Ray go away (G&A increased 24% in 2Q)? - They will be done by the end of the year.
12) Speaking of Darryl, do you know what his intentions are with his 1.1 million shares? - There is no bad blood between Darryl and the company, it's just a business decision to sell shares. Darryl wouldn't sell stock intentionally to hurt the company.
13) Long-term goals - Want to be a major player in the market, more focused on gel than PKI and MDS, leverage the GE Healthcare relationship to grow their sales.
14) Ron's background - Life sciences consultant previously. They (Darryl and Haseeb) wanted Ron to help with the transformation to becoming a public company. Ron previously brough Ultradata and Lexar Media public.
15) Anything else? - The company has been cash flow positive for the past 4 quarters and will remain that way from now on. While they have reported a loss in the last couple quarters, APNO will continue to lower costs and grow their business and should return to profitability soon.
dog - looks like we have lost the 1.15 bidder of the last few weeks.
Would like to hear how your phone call with Ron went. TIA. Jim
I finally got a return call from Ron and we spoke for about 35 minutes. Hopefully, I'll report on it tomorrow.
FWIW I share your frustration with the lack of communication from APNO - considering the very attractive life sciences space they're in and the enterprise value @ current prices I remain a holder, but the state of APNO affairs is no less irritating...
dog if you are going to sell this may be a good day with some activity today. Has'nt traded at all lately. I am still holding and will continue as long as news warrants. I may even buy some of your shares today. Jim
I just called Ron again and left another message. This is at least the 3rd time that I've called and no one has picked up the phone. It's 10:45 in California, so I know he's not on lunch.
I also left a message in the general message box. If I don't get a call from somebody by Wednesay, I'm selling everything. Unresponsive management is a big no-no in my book.
looks like Darryl just finished up selling his last 15K shares...not very impressive that he is selling at these levels but glad he may be done...
I don't think its that bad - not a material amount of stock (yet) - but certainly disappointing on a couple of fronts...
IMO, it is most defiitely a bad thing. I'm scared that since Darryl is no longer with the company or on the board, that he doesn't care what price he sells his shares at. He could continue to drive the stock down without any care for the company or its share price.
With that said, he only has 21,500 shares left to sell according to his 144 filing that I never saw (hehe).
Darryl sold another 68500 shares this week. He still has over 1 million shares left. I would really be concerned if he did not have so many shares left. But the fact he is selling now probably does indicate that he does not expect any news soon that will move the price. Guess I just continue to wait. Jim
I hear you - my criticism is that "shareholder communication" is actually worsening - I understand that it took APNO quite a while to get its finances under control post XTRN deal, which delayed upside on the stock - but the Company appears to now be in a position to move forward more aggressively and the stock seems to be just hanging out there...
bear APNO has been quite a tester for the patience of longs now for 3 plus years. I sometimes think my grandkids will be the benefactor of this one long after I am dead. LOL. Did just notice the ask moved up to a whopping 1.15 from 1.12. This after 1.12 was locked for a few minutes without a trade occuring. Jim
kinda disappointing - these guys sure haven't seemed to do much to get this stock established (albeit with the share liquidity issue)- as a matter of fact, APNO's communication with the market appears to be going DOWN this year - why do a reverse merger with a public shell for some cash, but then just ignore public stockholders? BTW I have requested information in the past via e-mails which have all been unanswered...I still consider APNO shares to be quite undervalued but my confidence on timely shareholder value enhancement is waning...
I tried to call Ron today...no answer and no return call.
This one is from last Monday (the 20th)...again it was only on the website.
NEW ALPHAIMAGER® EP SYSTEM FOR GEL DOCUMENTATION DELIVERS HIGH QUALITY IMAGES FOR BUDGET CONSCIOUS LABS
August 20, 2007 – Alpha Innotech Corp., San Leandro, California
Alpha Innotech Corp. (OTCBB:APNO), a leading provider of bioanalytical systems for drug discovery and life science research, announces its latest imaging system for fluorescent and colorimetric gels, the AlphaImager® EP. This system provides a high resolution, fully computer controlled camera, and comes with the newly engineered MultiImage® I light cabinet, which allows for a wide variety of fluorescent applications.
The AlphaImager® EP, a new addition to the AlphaImager® family of imaging systems, is designed to address the needs of budget conscious labs that demand high performance and quality in their UV and white light applications. The system’s scientific grade CCD camera has 1360X1024 pixel resolution and 12 bit dynamic range to ensure scientists can resolve close bands, as well as capture faint bands, making it ideal for accurate sample quantification.
The new MultiImage® I cabinet features a pull-out 302nm/365nm UV transilluminator with high/low settings, allowing excitation of multiple fluorescent dyes, as well as side white lights for easy focusing. To prevent accidental exposure to UV light, a safety switch automatically shuts off the UV light when the system door is open. The system footprints at 18.5” by 14.5”, making it ideal for labs with limited space.
The AlphaImager® EP system is customizable for different fluorescent dyes, including Ethidium Bromide, SYBR® Green and SYBR® Safe. For colorimetric applications, the scientist has the option to select a fold down white light table to back-illuminate absorption samples such as Coomassie stained and silver stained gels.
Lisa Valdin, Alpha Innotech’s Marketing Manager commented, “Based on customer feedback, we found most molecular biology labs need a simple solution to the question ‘What is the most cost-effective way I can archive and analyze my DNA and protein gels?’ The AlphaImager® EP answers this question by providing a flexible, easy to use system that fits into any lab budget.” The AlphaImager® EP is one member of the AlphaImager® family, which also consists of the AlphaImager® HP, Alpha Innotech’s industry leading imaging system for fluorescent and colorimetric gels. The AlphaImager® HP continues to set the standard for fluorescent application flexibility and ease-of-use for gel documentation.
The launch of the AlphaImager® EP coincides with the launch of Alpha Innotech’s new image analysis software, AlphaView™.
AlphaView™’s easy-to-use software tools for image acquisition, annotation and analysis allow the user to rapidly generate results and images for publications and presentations. AlphaView™ allows multiple image viewing and direct side by side image comparisons. Developing the software with the user in mind, Alpha Innotech has been developing image acquisition and analysis software for over 14 years.
I still consider this selling as pocket change for Darryl. I see no reason to be concerned, at this point, that he may be selling a large portion of his position.
When you call ask why the latest PR is only available on the web site? Seems to me that it was worth being released to the media. Thanks much. Jim
Now that I look back at it...that's the scary part!
Darryl has over 1.1 million shares left to sell. If he sold them all through open market transactions we're gonna get killed!
I'm going to try to call the company today. Anybody have any questions that they'd like answered?
Press release from Monday that never hit the newswires (it's only on the website from what I see).
ALPHA INNTEOCH RELEASES ALPHAVIEW, THE NEXT GENERATION OF IMAGE ANALYSIS SOFTWARE
August 27, 2007 – Alpha Innotech Corp., San Leandro, California
Alpha Innotech Corp. (OTCBB:APNO), a leading provider of bioanalytical systems for drug discovery and life science research, has released its latest innovation, AlphaView™, a software package for quantitative analysis of images from a wide range of biological samples.
AlphaView is designed to meet the requirements for image analysis in molecular biology labs, including analysis tools for determining band concentrations and molecular weight, colony counting scripts and determining macroarray intensities. AlphaView introduces the ability to view multiple images simultaneously, synchronized zooming and panning of multiple images, and the ability to save the analysis data in the software.
AlphaView replaces AlphaEase®FC, Alpha Innotech’s previous generation of image analysis software. “With the new added features in AlphaView, AlphaEaseFC customers will discover a more advanced software package that they are instantly familiar with,” said Lisa Valdin, Marketing Manager. “This ability to seamlessly transition from one software package to another was important for our thousands of users of AlphaEaseFC who will want the opportunity to update their software.”
A dramatic change to the software is the migration to one of the most contemporary programming language platforms. “The advantage of the new platform is that it will allow us to rapidly develop new analysis modules for the growing imaging area,” says Diping Che, Vice President of Research and Development. “As our customer’s applications expand, we need a software platform that will be able to seamlessly handle new developments.”
The launch of AlphaView coincided with the launch of the new AlphaImager® Family for gel documentation and analysis. This family consists of the AlphaImager HP, Alpha Innotech’s flagship product for streamlined gel documentation and analysis, and the AlphaImager EP, a more economical solution for labs that demand high performance.
it's the filings provider to Bloomberg so I don't know anything about it...
Is it a paid service?
I use secfilings.com to give me alerts and I also check the EDGAR website frequently. Usually they show 144 filings, but for some reason they don't show APNO's.
Keep us updated.
Washington Service
haha...I've got to get this service!
Last time we went through this you never told me the website, etc. that you use for this info. Would you care to share this time around?
not this again - my service shows D Ray filing on 08/23 TO SELL 100,000 shares...looks like he actually started selling on 08/17 and has made one Form 4 filing to date for 16.5K - that leaves 83.5K to go...
Where are you seeing that at?
I don't show anything on EDGAR about Ray selling more shares.
apparently more selling out of Darryl Ray (100K shares filed) so a bit of a drop to be expected...
Pretty decent volume today. But we're going in the wrong direction.
Pocket change for him. He still has a ton of shares. Jim
Followers
|
6
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
507
|
Created
|
04/16/04
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |